Skip to main content
Journal of Cachexia, Sarcopenia and Muscle logoLink to Journal of Cachexia, Sarcopenia and Muscle
editorial
. 2018 Oct 11;9(5):793–801. doi: 10.1002/jcsm.12356

Time to jump on the bandwagon: the Journal of Cachexia, Sarcopenia and Muscle in 2018

Stephan von Haehling 1,, Markus S Anker 2,3,4, Nicole Ebner 1, Stefan D Anker 3,4,5
PMCID: PMC6204581  PMID: 30311438

The Journal of Cachexia, Sarcopenia and Muscle (JCSM) was launched in September 2010, which means that we are publishing in the 9th year. Looking at PubMed, we found 445 entries when we searched the database on 7 September 2018. The overall number of publications has increased along with the number of issues from 4 to 5 in 2016 and again to 6 per year in 2017. Quite interestingly, though, the impact factor, published by Thomson Scientific in June this year, has also risen from 9.697 to 12.511. Of course, this is the 2017 impact factor, because the 2018 impact factor will become available only next year. It often comes as a surprise that the impact factor publication always bears the previous year. This has to do with the fact that it is calculated based on the items published and cited in the previous two full years. For JCSM, this means that the impact factor 2017 was calculated based on items cited and published in 2016 and 2017, but not on 2018 data as these are not available in full in the middle of the year. Looking at content and using the search term ‘J Cachexia Sarcopenia Muscle [jo] AND muscle [ti]’, we found 191 items published in JCSM that have the word ‘muscle’ in the manuscript title. For cachexia and sarcopenia, these numbers are 140 and 66, respectively.

JCSM is currently listed in Thomson Scientific only in two categories, in ‘Geriatrics and Gerontology’ and in ‘Medicine, General and Internal’ where it is ranked number 1 and number 8, respectively. We feel that listing in ‘Nutrition and Dietetics’ would also be appropriate, but currently, this is not the case (Tables 1, 2, 3). The best papers published in JCSM are listed in Tables 4, 5, 6, 7.1

Table 1.

Top 10 journals in the field ‘Medicine: General & Internal’ 2017

Rank Full journal title 2017 Journal impact factor Citable items published in 2015 and 2016 Issues per year
1 NEW ENGLAND JOURNAL OF MEDICINE 79.258 670 52
2 LANCET 53.254 645 51
3 JAMA‐JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 47.661 410 48
4 BMJ‐British Medical Journal 23.259 448 52
5 JAMA Internal Medicine 19.989 275 12
6 ANNALS OF INTERNAL MEDICINE 19.384 302 12
7 Nature Reviews Disease Primers 16.071 84 Continuous
8 Journal of Cachexia Sarcopenia and Muscle 12.511 88 6
9 PLOS MEDICINE 11.675 286 52
10 BMC Medicine 9.088 398 Continuous

Table 2.

Top 10 journals in the field ‘Nutrition & Dietetics’ 2017, where the Journal of Cachexia, Sarcopenia and Muscle is officially not listed

Rank Full journal title 2017 Journal impact factor Citable items published in 2015 and 2016 Issues per year
1 Annual Review of Nutrition 8.886 44 1
2 PROGRESS IN LIPID RESEARCH 8.435 69 4
3 Advances in Nutrition 6.853 177 6
4 AMERICAN JOURNAL OF CLINICAL NUTRITION 6.549 649 12
5 CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION 6.015 334 12
6 NUTRITION REVIEWS 5.788 132 12
7 International Journal of Behavioral Nutrition and Physical Activity 5.548 292 Continuous
8 CLINICAL NUTRITION 5.496 375 6
9 PROCEEDINGS OF THE NUTRITION SOCIETY 5.347 118 5
10 INTERNATIONAL JOURNAL OF OBESITY 5.151 503 12

Table 3.

Top 10 journals in the field ‘Geriatrics & Gerontology’ 2017

Rank Full journal title 2017 Journal impact factor Citable items published in 2015 and 2016 Issues per year
1 Journal of Cachexia Sarcopenia and Muscle 12.511 88 6
2 AGEING RESEARCH REVIEWS 8.973 146 8
3 AGING CELL 7.627 225 6
4 Journal of the American Medical Directors Association 5.325 388 12
5 Aging‐US 5.179 296 12
6 Aging and Disease 5.058 104 6
7 JOURNALS OF GERONTOLOGY SERIES A‐BIOLOGICAL SCIENCES AND MEDICAL SCIENCES 4.902 419 12
8 NEUROBIOLOGY OF AGING 4.454 738 12
9 JOURNAL OF THE AMERICAN GERIATRICS SOCIETY 4.155 627 12
10 Immunity & Ageing 4.019 53 Continuous

Table 4.

Top 10 of best cited original articles since first publication of the Journal of Cachexia, Sarcopenia and Muscle

First author Title Type Year Cites all time Reference
1 Dalton The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial Article 2011 135 3
2 Cesari Biomarkers of sarcopenia in clinical trials‐recommendations from the International Working Group on Sarcopenia Article 2012 99 4
3 Lainscak Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease Article 2011 69 5
4 Malmstrom SARC‐F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes Article 2016 66 6
5 Rozentryt The effects of a high‐caloric protein‐rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double‐blind pilot study Article 2010 64 7
6 Argiles The cachexia score (CASCO): a new tool for staging cachectic cancer patients Article 2011 56 8
7 Busquets Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance Article 2012 55 9
8 Kilgour Cancer‐related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer Article 2010 46 10
9 Chen Ghrelin prevents tumour‐ and cisplatin‐induced muscle wasting: characterization of multiple mechanisms involved Article 2015 45 11
10 Stephens Intramyocellular lipid droplets increase with progression of cachexia in cancer patients Article 2011 43 12

Table 5.

Top 30 of best cited articles published 2015 in the Journal of Cachexia, Sarcopenia and Muscle and cited in 2017

First author Title Type Cites in 2017 Reference
1 von Haehling Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015 Editorial 73 13
2 Bowen Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training Review 38 14
3 Calvani Biomarkers for physical frailty and sarcopenia: state of the science and future developments Review 27 15
4 Ezeoke Pathophysiology of anorexia in the cancer cachexia syndrome Review 26 16
5 Chen Ghrelin prevents tumour‐ and cisplatin‐induced muscle wasting: characterization of multiple mechanisms involved Article 24 11
6 Drescher Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment Review 20 17
7 Sasso A framework for prescription in exercise‐oncology research Editorial 18 18
8 Fearon Request for regulatory guidance for cancer cachexia intervention trials Editorial 17 19
9 Anker Cachexia: a nutritional syndrome? Editorial 15 20
10 Mangner Skeletal muscle alterations in chronic heart failure: differential effects on quadriceps and diaphragm Article 14 21
11 Grande Exercise for cancer cachexia in adults: executive summary of a Cochrane Collaboration systematic review Review 13 22
12 Cooper Understanding and managing cancer‐related weight loss and anorexia: insights from a systematic review of qualitative research Review 12 23
13 Dupuy Searching for a relevant definition of sarcopenia: results from the cross‐sectional EPIDOS study Article 11 24
14 Stephens Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients Article 11 25
15 Matsuo Fibronectin type III domain containing 5 expression in skeletal muscle in chronic heart failure‐relevance of inflammatory cytokines Article 11 26
16 Lerner Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients Article 11 27
17 Morley Rapid screening for sarcopenia Editorial 11 28
18 Anker Evidence for partial pharmaceutical reversal of the cancer anorexia‐cachexia syndrome: the case of anamorelin Editorial 11 29
19 Gu Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma Article 10 30
20 Dev Hypermetabolism and symptom burden in advanced cancer patients evaluated in a cachexia clinic Article 10 31
21 Dwarkasing Differences in food intake of tumour‐bearing cachectic mice are associated with hypothalamic serotonin signalling Article 9 32
22 Gielen Endocrine determinants of incident sarcopenia in middle‐aged and elderly European men Article 8 33
23 van Dijk Effects of oral meal feeding on whole body protein breakdown and protein synthesis in cachectic pancreatic cancer patients Article 8 34
24 Wakabayashi Skeletal muscle mass is associated with severe dysphagia in cancer patients Article 8 35
25 Kob Gender‐specific differences in the development of sarcopenia in the rodent model of the ageing high‐fat rat Article 8 36
26 Marino Activin‐beta(C) modulates cachexia by repressing the ubiquitin‐proteasome and autophagic degradation pathways Article 8 37
27 van Norren Behavioural changes are a major contributing factor in the reduction of sarcopenia in caloric‐restricted ageing mice Article 7 38
28 Haruta One‐year intranasal application of growth hormone releasing peptide‐2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient Article 6 39
29 Faber Improved body weight and performance status and reduced serum PGE(2) levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro‐esophageal junction Article 5 40
30 Moryoussef Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib Article 5 41

Table 6.

Top 30 of best cited articles published 2016 in the Journal of Cachexia, Sarcopenia and Muscle and cited in 2017

First author Title Type Cites in 2017 Reference
1 Malmstrom SARC‐F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes Article 31 5
2 Coats Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo‐controlled, international multicentre phase II study (the ACT‐ONE trial) Article 24 42
3 Montano‐Loza Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis Article 18 43
4 Brown Sarcopenia and mortality among a population‐based sample of community‐dwelling older adults Article 18 44
5 Rutten Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients Article 17 45
6 Tyrovolas Factors associated with skeletal muscle mass, sarcopenia, and sarcopenic obesity in older adults: a multi‐continent study Article 16 46
7 Sanders Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective Review 16 47
8 Loncar Cardiac cachexia: hic et nunc Review 15 48
9 von Haehling Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016 Editorial 15 49
10 Sente Adiponectin resistance in skeletal muscle: pathophysiological implications in chronic heart failure Review 14 50
11 Leong Reference ranges of handgrip strength from 125,462 healthy adults in 21 countries: a prospective urban rural epidemiologic (PURE) study Article 12 51
12 Sakuma p62/SQSTM1 but not LC3 is accumulated in sarcopenic muscle of mice Article 12 52
13 Pinto Impact of creatine supplementation in combination with resistance training on lean mass in the elderly Article 12 53
14 Banach Discussion around statin discontinuation in older adults and patients with wasting diseases Editorial 12 54
15 Batista Cachexia‐associated adipose tissue morphological rearrangement in gastrointestinal cancer patients Article 11 55
16 Go Prognostic impact of sarcopenia in patients with diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone Article 11 56
17 Anker Welcome to the ICD‐10 code for sarcopenia Editorial 11 57
18 Lainscak ACT‐ONE‐ACTION at last on cancer cachexia by adapting a novel action beta‐blocker Editorial 11 58
19 Barbosa‐Silva Prevalence of sarcopenia among community‐dwelling elderly of a medium‐sized South American city: results of the COMO VAI? study Article 10 59
20 Ferraro Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine Article 10 60
21 Foong Accelerometer‐determined physical activity, muscle mass, and leg strength in community‐dwelling older adults Article 10 61
22 Lewis Increased expression of H19/miR‐675 is associated with a low fat‐free mass index in patients with COPD Article 10 62
23 Penna Effect of the specific proteasome inhibitor bortezomib on cancer‐related muscle wasting Article 10 63
24 Musolino Megestrol acetate improves cardiac function in a model of cancer cachexia‐induced cardiomyopathy by autophagic modulation Article 9 64
25 Berger Dysfunction of respiratory muscles in critically ill patients on the intensive care unit Review 9 65
26 de Vries Patient‐centred physical therapy is (cost‐) effective in increasing physical activity and reducing frailty in older adults with mobility problems: a randomized controlled trial with 6 months follow‐up Article 8 66
27 Patel Growth differentiation factor‐15 is associated with muscle mass in chronic obstructive pulmonary disease and promotes muscle wasting in vivo Article 8 67
28 Szulc High risk of fall, poor physical function, and low grip strength in men with fracture—the STRAMBO study Article 8 68
29 Lodka Muscle RING‐finger 2 and 3 maintain striated‐muscle structure and function Article 8 69
30 Nederveen Skeletal muscle satellite cells are located at a closer proximity to capillaries in healthy young compared with older men Article 7 70

Table 7.

Top 30 of best cited articles published 2017 in the Journal of Cachexia, Sarcopenia and Muscle

First author Title Type Cites all time Reference
1 Kalafateli Malnutrition and sarcopenia predict post‐liver transplantation outcomes independently of the Model for End‐stage Liver Disease score Article 28 71
2 Sahebkar Curcumin: an effective adjunct in patients with statin‐associated muscle symptoms? Review 18 72
3 van Dijk Low skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer Article 15 73
4 Mochamat A systematic review on the role of vitamins, minerals, proteins, and other supplements for the treatment of cachexia in cancer: a European Palliative Care Research Centre cachexia project Review 14 74
5 Snijders Muscle fibre capillarization is a critical factor in muscle fibre hypertrophy during resistance exercise training in older men Article 11 75
6 Calvani Systemic inflammation, body composition, and physical performance in old community‐dwellers Article 11 76
7 Boengler Mitochondria and ageing: role in heart, skeletal muscle and adipose tissue Review 11 77
8 Klassen Muscle strength in breast cancer patients receiving different treatment regimes Article 10 78
9 Kittiskulnam Sarcopenia among patients receiving hemodialysis: weighing the evidence Article 10 79
10 Cheung Androgen deprivation causes selective deficits in the biomechanical leg muscle function of men during walking: a prospective case–control study Article 10 80
11 Verzola Toll‐like receptor 4 signalling mediates inflammation in skeletal muscle of patients with chronic kidney disease Article 10 81
12 Solheim A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer Article 9 82
13 Beaudart Validation of the SarQoL (R), a specific health‐related quality of life questionnaire for Sarcopenia Article 9 83
14 Chan Integrated care for geriatric frailty and sarcopenia: a randomized control trial Article 9 84
15 Holecek Beta‐hydroxy‐beta‐methylbutyrate supplementation and skeletal muscle in healthy and muscle‐wasting conditions Review 9 85
16 van de Bool A randomized clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD Article 8 86
17 Reijnierse Assessment of maximal handgrip strength: how many attempts are needed? Article 8 87
18 St‐Jean‐Pelletier The impact of ageing, physical activity, and pre‐frailty on skeletal muscle phenotype, mitochondrial content, and intramyocellular lipids in men Article 8 88
19 Dodds Prevalence and incidence of sarcopenia in the very old: findings from the Newcastle 85+ Study Article 8 89
20 dos Santos Sarcopenia and physical independence in older adults: the independent and synergic role of muscle mass and muscle function Article 8 90
21 van Vugt A comparative study of software programmes for cross‐sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patients Article 8 91
22 Molfino Cancer anorexia: hypothalamic activity and its association with inflammation and appetite‐regulating peptides in lung cancer Article 8 92
23 Goossens Premorbid obesity, but not nutrition, prevents critical illness‐induced muscle wasting and weakness Article 8 93
24 Lipina Lipid modulation of skeletal muscle mass and function Review 8 94
25 Clark Effect of beta‐adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial Article 7 95
26 Rutten Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer Article 7 96
27 Johns New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss Article 7 97
28 Gonzalez‐Freire The Human Skeletal Muscle Proteome Project: a reappraisal of the current literature Review 7 98
29 Morley Anorexia of ageing: a key component in the pathogenesis of both sarcopenia and cachexia Editorial 7 99
30 Baracos Psoas as a sentinel muscle for sarcopenia: a flawed premise Editorial 7 100

Looking at JCSM as the mother, there are now two daughters that have started to flourish: JCSM—Clinical Reports (http://www.jcsm-clinical-reports.info) started in July 2016 and is dedicated to clinical reports in the strictest sense of the word, i.e. original and review papers from the clinical field of wasting disorders in the broadest sense including case reports. The other one, JCSM—Rapid Communications (http://www.jcsm-rapid-communications.info), was launched a little later in January this year and is supposed to publish scientific papers from a very broad field including original and review papers from clinical as well as basic science groups. It is interesting to see how rapidly both journals are growing, underlining the need for more than one journal in the area of body wasting that can still be considered a niche. Of course, we welcome submissions to all three journals.

Finally, we would like to draw your attention to the up‐coming Cachexia Conference, to be held in Maastricht, the Netherlands, from December 7 to 9, 2018. The conference remains a source of stimulating ideas and exchange between clinicans and researchers in the field of cachexia and wasting. More information is available at http://society-scwd.org.

Conflict of interest

None declared.

Acknowledgements

The authors certify that they comply with the ethical guidelines for authorship and publishing of the Journal of Cachexia, Sarcopenia and Muscle.2

von Haehling, S. , Anker, M. S. , Ebner, N. , and Anker, S. D. (2018) Time to jump on the bandwagon: the Journal of Cachexia, Sarcopenia and Muscle in 2018. Journal of Cachexia, Sarcopenia and Muscle, 9: 793–801. 10.1002/jcsm.12356.

References

  • 1. http://www.webofknowledge.com (accessed 31/08/2018).
  • 2. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2017. J Cachexia Sarcopenia Muscle 2017;8:1081–1083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, et al. The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial. J Cachexia Sarcopenia Muscle 2011;2:153–161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Cesari M, Fielding RA, Pahor M, Goodpaster B, Hellerstein M, van Kan GA, et al. Biomarkers of sarcopenia in clinical trials‐recommendations from the International Working Group on Sarcopenia. J Cachexia Sarcopenia Muscle 2012;3:181–19090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Lainscak M, von Haehling S, Doehner W, Sarc I, Jeric T, Ziherl K, et al. Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. J Cachexia Sarcopenia Muscle 2011;2:81–86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC‐F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle 2016;7:28–36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Rozentryt P, von Haehling S, Lainscak M, Nowak JU, Kalantar‐Zadeh K, Polonski L, et al. The effects of a high‐caloric protein‐rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double‐blind pilot study. J Cachexia Sarcopenia Muscle 2010;1:35–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Argilés JM, López‐Soriano FJ, Toledo M, Betancourt A, Serpe R, Busquets S. The cachexia score (CASCO): a new tool for staging cachectic cancer patients. J Cachexia Sarcopenia Muscle 2011;2:87–93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Busquets S, Toledo M, Orpí M, Massa D, Porta M, Capdevila E, et al. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachexia Sarcopenia Muscle 2012;3:37–43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Kilgour RD, Vigano A, Trutschnigg B, Hornby L, Lucar E, Bacon SL, et al. Cancer‐related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer. J Cachexia Sarcopenia Muscle 2010;1:177–185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Chen JA, Splenser A, Guillory B, Luo J, Mendiratta M, Belinova B, et al. Ghrelin prevents tumour‐ and cisplatin‐induced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sarcopenia Muscle 2015;6:132–14343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Stephens NA, Skipworth RJ, Macdonald AJ, Greig CA, Ross JA, Fearon KC. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J Cachexia Sarcopenia Muscle 2011;2:111–117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015. J Cachexia Sarcopenia Muscle 2015;6:315–3166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 2015;6:197–207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Calvani R, Marini F, Cesari M, Tosato M, Anker SD, von Haehling S, et al. Marzetti E; SPRINTT consortium. Biomarkers for physical frailty and sarcopenia: state of the science and future developments. J Cachexia Sarcopenia Muscle 2015;6:278–28686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Ezeoke CC, Morley JE. Pathophysiology of anorexia in the cancer cachexia syndrome. J Cachexia Sarcopenia Muscle 2015;6:287–302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Drescher C, Konishi M, Ebner N, Springer J. Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment. J Cachexia Sarcopenia Muscle 2015;6:303–31111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for prescription in exercise‐oncology research. J Cachexia Sarcopenia Muscle 2015;6:115–12424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Fearon K, Argiles JM, Baracos VE, Bernabei R, Coats A, Crawford J, et al. Request for regulatory guidance for cancer cachexia intervention trials. J Cachexia Sarcopenia Muscle 2015;6:272–2744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Anker SD, Morley JE. Cachexia: a nutritional syndrome? J Cachexia Sarcopenia Muscle 2015;6:269–27171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Mangner N, Weikert B, Bowen TS, Sandri M, Höllriegel R, Erbs S, et al. Skeletal muscle alterations in chronic heart failure: differential effects on quadriceps and diaphragm. J Cachexia Sarcopenia Muscle 2015;6:381–39090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Grande AJ, Silva V, Maddocks M. Exercise for cancer cachexia in adults: executive summary of a Cochrane Collaboration systematic review. J Cachexia Sarcopenia Muscle 2015;6:208–21111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Cooper C, Burden ST, Cheng H, Molassiotis A. Understanding and managing cancer‐related weight loss and anorexia: insights from a systematic review of qualitative research. J Cachexia Sarcopenia Muscle 2015;6:99–111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Dupuy C, Lauwers‐Cances V, Guyonnet S, Gentil C, Abellan Van Kan G, Beauchet O, et al. Searching for a relevant definition of sarcopenia: results from the cross‐sectional EPIDOS study. J Cachexia Sarcopenia Muscle 2015;6:144–15454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Stephens NA, Skipworth RJ, Gallagher IJ, Greig CA, Guttridge DC, Ross JA, et al. Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients. J Cachexia Sarcopenia Muscle 2015;6:53–61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Matsuo Y, Gleitsmann K, Mangner N, Werner S, Fischer T, Bowen TS, et al. Fibronectin type III domain containing 5 expression in skeletal muscle in chronic heart failure‐relevance of inflammatory cytokines. J Cachexia Sarcopenia Muscle 2015;6:62–72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Lerner L, Hayes TG, Tao N, Krieger B, Feng B, Wu Z, et al. Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients. J Cachexia Sarcopenia Muscle 2015;6:317–32424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Morley JE, Cao L. Rapid screening for sarcopenia. J Cachexia Sarcopenia Muscle 2015;6:312–3144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Anker SD, Coats AJ, Morley JE. Evidence for partial pharmaceutical reversal of the cancer anorexia‐cachexia syndrome: the case of anamorelin. J Cachexia Sarcopenia Muscle 2015;6:275–2777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Gu W, Zhang G, Sun L, Ma Q, Cheng Y, Zhang H, et al. Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma. J Cachexia Sarcopenia Muscle 2015;6:222–23030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Dev R, Hui D, Chisholm G, Delgado‐Guay M, Dalal S, Del Fabbro E, et al. Hypermetabolism and symptom burden in advanced cancer patients evaluated in a cachexia clinic. J Cachexia Sarcopenia Muscle 2015;6:95–988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Dwarkasing JT, Boekschoten MV, Argilès JM, van Dijk M, Busquets S, Penna F, et al. Differences in food intake of tumour‐bearing cachectic mice are associated with hypothalamic serotonin signalling. J Cachexia Sarcopenia Muscle 2015;6:84–94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Gielen E, O'Neill TW, Pye SR, Adams JE, Wu FC, Laurent MR, et al. Endocrine determinants of incident sarcopenia in middle‐aged and elderly European men. J Cachexia Sarcopenia Muscle 2015;6:242–25252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. van Dijk DP, van de Poll MC, Moses AG, Preston T, Olde Damink SW, Rensen SS, et al. Effects of oral meal feeding on whole body protein breakdown and protein synthesis in cachectic pancreatic cancer patients. J Cachexia Sarcopenia Muscle 2015;6:212–22121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Wakabayashi H, Matsushima M, Uwano R, Watanabe N, Oritsu H, Shimizu Y. Skeletal muscle mass is associated with severe dysphagia in cancer patients. J Cachexia Sarcopenia Muscle 2015;6:351–3577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Kob R, Fellner C, Bertsch T, Wittmann A, Mishura D, Sieber CC, et al. Gender‐specific differences in the development of sarcopenia in the rodent model of the ageing high‐fat rat. J Cachexia Sarcopenia Muscle 2015;6:181–19191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Marino FE, Risbridger G, Gold E. Activin‐βC modulates cachexia by repressing the ubiquitin‐proteasome and autophagic degradation pathways. J Cachexia Sarcopenia Muscle 2015;6:365–38080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. van Norren K, Rusli F, van Dijk M, Lute C, Nagel J, Dijk FJ, et al. Behavioural changes are a major contributing factor in the reduction of sarcopenia in caloric‐restricted ageing mice. J Cachexia Sarcopenia Muscle 2015;6:253–26868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Haruta I, Fuku Y, Kinoshita K, Yoneda K, Morinaga A, Amitani M, et al. One‐year intranasal application of growth hormone releasing peptide‐2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient. J Cachexia Sarcopenia Muscle 2015;6:237–241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Faber J, Uitdehaag MJ, Spaander M, van Steenbergen‐Langeveld S, Vos P, Berkhout M, et al. Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro‐esophageal junction. J Cachexia Sarcopenia Muscle 2015;6:32–44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Moryoussef F, Dhooge M, Volet J, Barbe C, Brezault C, Hoeffel C, et al. Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib. J Cachexia Sarcopenia Muscle 2015;6:343–350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Stewart Coats AJ, Ho GF, Prabhash K, von Haehling S, Tilson J, Brown R, et al. Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo‐controlled, international multicentre phase II study (the ACT‐ONE trial). J Cachexia Sarcopenia Muscle 2016;7:355–365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Montano‐Loza AJ, Angulo P, Meza‐Junco J, Prado CM, Sawyer MB, Beaumont C, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle 2016;7:126–135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Brown JC, Harhay MO, Harhay MN. Sarcopenia and mortality among a population‐based sample of community‐dwelling older adults. J Cachexia Sarcopenia Muscle 2016;7:290–298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Rutten IJ, van Dijk DP, Kruitwagen RF, Beets‐Tan RG, Olde Damink SW, van Gorp T. Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle 2016;7:458–466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Tyrovolas S, Koyanagi A, Olaya B, Ayuso‐Mateos JL, Miret M, Chatterji S, et al. Factors associated with skeletal muscle mass, sarcopenia, and sarcopenic obesity in older adults: a multi‐continent study. J Cachexia Sarcopenia Muscle 2016;7:312–321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Sanders KJ, Kneppers AE, van de Bool C, Langen RC, Schols AM. Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective. J Cachexia Sarcopenia Muscle 2016;7:5–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Loncar G, Springer J, Anker M, Doehner W, Lainscak M. Cardiac cachexia: hic et nunc. J Cachexia Sarcopenia Muscle 2016;7:246–260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. von Haehling S, Anker MS, Anker SD. Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016. J Cachexia Sarcopenia Muscle 2016;7:507–509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Sente T, Van Berendoncks AM, Hoymans VY, Vrints CJ. Adiponectin resistance in skeletal muscle: pathophysiological implications in chronic heart failure. J Cachexia Sarcopenia Muscle 2016;7:261–274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Leong DP, Teo KK, Rangarajan S, Kutty VR, Lanas F, Hui C, et al. Reference ranges of handgrip strength from 125,462 healthy adults in 21 countries: a prospective urban rural epidemiologic (PURE) study. J Cachexia Sarcopenia Muscle 2016;7:535–546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Sakuma K, Kinoshita M, Ito Y, Aizawa M, Aoi W, Yamaguchi A. p62/SQSTM1 but not LC3 is accumulated in sarcopenic muscle of mice. J Cachexia Sarcopenia Muscle 2016;7:204–212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Pinto CL, Botelho PB, Carneiro JA, Mota JF. Impact of creatine supplementation in combination with resistance training on lean mass in the elderly. J Cachexia Sarcopenia Muscle 2016;7:413–421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Banach M, Serban MC. Discussion around statin discontinuation in older adults and patients with wasting diseases. J Cachexia Sarcopenia Muscle 2016;7:396–399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Batista ML Jr, Henriques FS, Neves RX, Olivan MR, Matos‐Neto EM, Alcântara PS, et al. Cachexia‐associated adipose tissue morphological rearrangement in gastrointestinal cancer patients. J Cachexia Sarcopenia Muscle 2016;7:37–47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Go SI, Park MJ, Song HN, Kim HG, Kang MH, Lee HR, et al. Prognostic impact of sarcopenia in patients with diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Cachexia Sarcopenia Muscle 2016;7:567–576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Anker SD, Morley JE, von Haehling S. Welcome to the ICD‐10 code for sarcopenia. J Cachexia Sarcopenia Muscle 2016;7:512–514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Lainscak M, Laviano A. ACT‐ONE‐ACTION at last on cancer cachexia by adapting a novel action beta‐blocker. J Cachexia Sarcopenia Muscle 2016;7:400–402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Barbosa‐Silva TG, Bielemann RM, Gonzalez MC, Menezes AM. Prevalence of sarcopenia among community‐dwelling elderly of a medium‐sized South American city: results of the COMO VAI? study. J Cachexia Sarcopenia Muscle 2016;7:136–143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Ferraro E, Pin F, Gorini S, Pontecorvo L, Ferri A, Mollace V, et al. Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine. J Cachexia Sarcopenia Muscle 2016;7:449–457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61. Foong YC, Chherawala N, Aitken D, Scott D, Winzenberg T, Jones G. Accelerometer‐determined physical activity, muscle mass, and leg strength in community‐dwelling older adults. J Cachexia Sarcopenia Muscle 2016;7:275–283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. Lewis A, Lee JY, Donaldson AV, Natanek SA, Vaidyanathan S, Man WD, et al. Increased expression of H19/miR‐675 is associated with a low fat‐free mass index in patients with COPD. J Cachexia Sarcopenia Muscle 2016;7:330–344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63. Penna F, Bonetto A, Aversa Z, Minero VG, Rossi Fanelli F, Costelli P, et al. Effect of the specific proteasome inhibitor bortezomib on cancer‐related muscle wasting. J Cachexia Sarcopenia Muscle 2016;7:345–354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Musolino V, Palus S, Tschirner A, Drescher C, Gliozzi M, Carresi C, et al. Megestrol acetate improves cardiac function in a model of cancer cachexia‐induced cardiomyopathy by autophagic modulation. J Cachexia Sarcopenia Muscle 2016;7:555–566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Berger D, Bloechlinger S, von Haehling S, Doehner W, Takala J, Z'Graggen WJ, et al. Dysfunction of respiratory muscles in critically ill patients on the intensive care unit. J Cachexia Sarcopenia Muscle 2016;7:403–412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66. de Vries NM, Staal JB, van der Wees PJ, Adang EM, Akkermans R, Olde Rikkert MG, et al. Patient‐centred physical therapy is (cost‐) effective in increasing physical activity and reducing frailty in older adults with mobility problems: a randomized controlled trial with 6 months follow‐up. J Cachexia Sarcopenia Muscle 2016;7:422–435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Patel MS, Lee J, Baz M, Wells CE, Bloch S, Lewis A, et al. Growth differentiation factor‐15 is associated with muscle mass in chronic obstructive pulmonary disease and promotes muscle wasting in vivo. J Cachexia Sarcopenia Muscle 2016;7:436–448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Szulc P, Feyt C, Chapurlat R. High risk of fall, poor physical function, and low grip strength in men with fracture—the STRAMBO study. J Cachexia Sarcopenia Muscle 2016;7:299–311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Lodka D, Pahuja A, Geers‐Knörr C, Scheibe RJ, Nowak M, Hamati J, et al. Muscle RING‐finger 2 and 3 maintain striated‐muscle structure and function. J Cachexia Sarcopenia Muscle 2016;7:165–180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70. Nederveen JP, Joanisse S, Snijders T, Ivankovic V, Baker SK, Phillips SM, et al. Skeletal muscle satellite cells are located at a closer proximity to capillaries in healthy young compared with older men. J Cachexia Sarcopenia Muscle 2016;7:547–554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71. Kalafateli M, Mantzoukis K, Choi Yau Y, Mohammad AO, Arora S, Rodrigues S, et al. Malnutrition and sarcopenia predict post‐liver transplantation outcomes independently of the Model for End‐stage Liver Disease score. J Cachexia Sarcopenia Muscle 2017;8:113–121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72. Sahebkar A, Saboni N, Pirro M, Banach M. Curcumin: an effective adjunct in patients with statin‐associated muscle symptoms? J Cachexia Sarcopenia Muscle 2017;8:19–24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73. van Dijk DP, Bakens MJ, Coolsen MM, Rensen SS, van Dam RM, Bours MJ, et al. Low skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer. J Cachexia Sarcopenia Muscle 2017;8:317–326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Mochamat CH, Marinova M, Kaasa S, Stieber C, Conrad R, Radbruch L, et al. A systematic review on the role of vitamins, minerals, proteins, and other supplements for the treatment of cachexia in cancer: a European Palliative Care Research Centre cachexia project. J Cachexia Sarcopenia Muscle 2017;8:25–39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75. Snijders T, Nederveen JP, Joanisse S, Leenders M, Verdijk LB, van Loon LJ, et al. Muscle fibre capillarization is a critical factor in muscle fibre hypertrophy during resistance exercise training in older men. J Cachexia Sarcopenia Muscle 2017;8:267–276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Calvani R, Marini F, Cesari M, Buford TW, Manini TM, Pahor M, et al. Systemic inflammation, body composition, and physical performance in old community‐dwellers. J Cachexia Sarcopenia Muscle 2017;8:69–77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77. Boengler K, Kosiol M, Mayr M, Schulz R, Rohrbach S. Mitochondria and ageing: role in heart, skeletal muscle and adipose tissue. J Cachexia Sarcopenia Muscle 2017;8:349–369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78. Klassen O, Schmidt ME, Ulrich CM, Schneeweiss A, Potthoff K, Steindorf K, et al. Muscle strength in breast cancer patients receiving different treatment regimes. J Cachexia Sarcopenia Muscle 2017;8:305–316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79. Kittiskulnam P, Carrero JJ, Chertow GM, Kaysen GA, Delgado C, Johansen KL. Sarcopenia among patients receiving hemodialysis: weighing the evidence. J Cachexia Sarcopenia Muscle 2017;8:57–68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80. Cheung AS, Gray H, Schache AG, Hoermann R, Lim Joon D, Zajac JD, et al. Androgen deprivation causes selective deficits in the biomechanical leg muscle function of men during walking: a prospective case–control study. J Cachexia Sarcopenia Muscle 2017;8:102–112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81. Verzola D, Bonanni A, Sofia A, Montecucco F, D'Amato E, Cademartori V, et al. Toll‐like receptor 4 signalling mediates inflammation in skeletal muscle of patients with chronic kidney disease. J Cachexia Sarcopenia Muscle 2017;8:131–144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82. Solheim TS, Laird BJA, Balstad TR, Stene GB, Bye A, Johns N, et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle 2017;8:778–788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83. Beaudart C, Biver E, Reginster JY, Rizzoli R, Rolland Y, Bautmans I, et al. Validation of the SarQoL®, a specific health‐related quality of life questionnaire for Sarcopenia. J Cachexia Sarcopenia Muscle 2017;8:238–244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84. Chan DD, Tsou HH, Chang CB, Yang RS, Tsauo JY, Chen CY, et al. Integrated care for geriatric frailty and sarcopenia: a randomized control trial. J Cachexia Sarcopenia Muscle 2017;8:78–88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85. Holeček M. Beta‐hydroxy‐beta‐methylbutyrate supplementation and skeletal muscle in healthy and muscle‐wasting conditions. J Cachexia Sarcopenia Muscle 2017;8:529–541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86. van de Bool C, Rutten EPA, van Helvoort A, Franssen FME, Wouters EFM, Schols AMWJ. A randomized clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD. J Cachexia Sarcopenia Muscle 2017;8:748–758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87. Reijnierse EM, de Jong N, Trappenburg MC, Blauw GJ, Butler‐Browne G, Gapeyeva H, et al. Assessment of maximal handgrip strength: how many attempts are needed? J Cachexia Sarcopenia Muscle 2017;8:466–474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88. St‐Jean‐Pelletier F, Pion CH, Leduc‐Gaudet JP, Sgarioto N, Zovilé I, Barbat‐Artigas S, et al. The impact of ageing, physical activity, and pre‐frailty on skeletal muscle phenotype, mitochondrial content, and intramyocellular lipids in men. J Cachexia Sarcopenia Muscle 2017;8:213–228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89. Dodds RM, Granic A, Davies K, Kirkwood TB, Jagger C, Sayer AA. Prevalence and incidence of sarcopenia in the very old: findings from the Newcastle 85+ Study. J Cachexia Sarcopenia Muscle 2017;8:229–237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90. Dos Santos L, Cyrino ES, Antunes M, Santos DA, Sardinha LB. Sarcopenia and physical independence in older adults: the independent and synergic role of muscle mass and muscle function. J Cachexia Sarcopenia Muscle 2017;8:245–250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91. van Vugt JL, Levolger S, Gharbharan A, Koek M, Niessen WJ, Burger JW, et al. A comparative study of software programmes for cross‐sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patients. J Cachexia Sarcopenia Muscle 2017;8:285–297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92. Molfino A, Iannace A, Colaiacomo MC, Farcomeni A, Emiliani A, Gualdi G, et al. Cancer anorexia: hypothalamic activity and its association with inflammation and appetite‐regulating peptides in lung cancer. J Cachexia Sarcopenia Muscle 2017;8:40–47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93. Goossens C, Marques MB, Derde S, Vander Perre S, Dufour T, Thiessen SE, et al. Premorbid obesity, but not nutrition, prevents critical illness‐induced muscle wasting and weakness. J Cachexia Sarcopenia Muscle 2017;8:89–101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94. Lipina C, Hundal HS. Lipid modulation of skeletal muscle mass and function. J Cachexia Sarcopenia Muscle 2017;8:190–201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95. Clark AL, Coats AJS, Krum H, Katus HA, Mohacsi P, Salekin D, et al. Effect of beta‐adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. J Cachexia Sarcopenia Muscle 2017;8:549–556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96. Rutten IJG, Ubachs J, Kruitwagen RFPM, Beets‐Tan RGH, Olde Damink SWM, Van Gorp T. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. J Cachexia Sarcopenia Muscle 2017;8:630–638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97. Johns N, Stretch C, Tan BH, Solheim TS, Sørhaug S, Stephens NA, et al. New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. J Cachexia Sarcopenia Muscle 2017;8:122–130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98. Gonzalez‐Freire M, Semba RD, Ubaida‐Mohien C, Fabbri E, Scalzo P, Højlund K, et al. The Human Skeletal Muscle Proteome Project: a reappraisal of the current literature. J Cachexia Sarcopenia Muscle 2017;8:5–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99. Morley JE. Anorexia of ageing: a key component in the pathogenesis of both sarcopenia and cachexia. J Cachexia Sarcopenia Muscle 2017;8:523–526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100. Baracos VE. Psoas as a sentinel muscle for sarcopenia: a flawed premise. J Cachexia Sarcopenia Muscle 2017;8:527–528. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Cachexia, Sarcopenia and Muscle are provided here courtesy of Wiley

RESOURCES